One of my Daily Drugs is name-brand only; CFI Care (not its real initials) specifies a copay of $75 a month for it, and will presumably do so until such time as a generic version becomes available, whenever that may be. A Mumbai-based drug company announced three years ago that the FDA had granted them tentative approval for a generic, but the patent apparently doesn’t expire until 2020. In the meantime, CFI Care gets to pay $12.32 per tablet.
Ongoing bladder issues led my doctor to recommend a trial of yet another brand-name drug: he handed over three boxes of seven tablets each. It worked fairly well. There exists a generic, but distribution seems to be blocked for now, so the pharmacy duly boxed me up 90 days’ worth, with a caution from the pharm tech that “this is very expensive.” Well, yeah, I knew that:
A 2006 cost-effectiveness study found that 5 mg solifenacin had the lowest cost and highest effectiveness among anticholinergic drugs used to treat overactive bladder in the United States, with an average medical cost per successfully treated patient of $6863 per year.
This was $18.80 a tablet in 2006. It’s come down some since then; CFI Care got to fork over $9.72 a tab. Still, it’s another $75 a month out of my pocket. Fortunately, Martin Shkreli doesn’t seem to be involved.